Cervista HR and HPV 16/18 assays vs hybrid capture 2 assay: Outcome comparison in women with negative cervical cytology

Elizabeth M. Kurian, Mandi Lee Caporelli, Stephen Baker, Bruce Woda, Ediz F. Cosar, Lloyd Hutchinson

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Sensitive and specific assays for human papillomavirus (HPV) are essential for patient management. In this study, we directly compared the efficacy of the Hybrid Capture 2 (HC2; Qiagen, Valencia, CA) and Cervista assays (Hologic, Madison, WI). Consecutive cervical cytology specimens (n = 601) were tested using HC2, Cervista HR, and Cervista HPV 16/18 with analysis of only cytology-negative cases (n = 533). Results indicated no significant difference (P = .458) in prevalence rates between HC2 (7.5%) and Cervista HR (8.5%). The Cervista 16/18 prevalence was 1.6%. The negative percentage of agreement was 95.1% (468/492) vs a 70% (28/40) positive percentage of agreement. No false-negative results were detected by the Cervista internal DNA control. Our data show 29 discordant positive results (12 HC2 and 17 Cervista HR), suggesting some women with negative cytology may be triaged for unnecessary follow-up with either assay. For clinical screening, Cervista HR and HC2 are comparable and, by extension, should provide excellent negative predictive value for histologically relevant disease.

Original languageEnglish (US)
Pages (from-to)808-816
Number of pages9
JournalAmerican journal of clinical pathology
Volume136
Issue number5
DOIs
StatePublished - Nov 1 2011

Keywords

  • Cervista 16/18
  • Cervista HPV HR
  • Cytology
  • HC2
  • HPV molecular assay
  • High-risk human papillomavirus
  • Hybrid capture 2
  • Papanicolaou smears

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Cervista HR and HPV 16/18 assays vs hybrid capture 2 assay: Outcome comparison in women with negative cervical cytology'. Together they form a unique fingerprint.

  • Cite this